Identificación del alelo HLA B*57: 01 en una población militar, de Lima-Perú / Identification of the allele HLA B*57: 01 in a military population, from Lima-Peru

El alelo HLA B*57:01 es un marcador genético asociado con la hipersensibilidad al fármaco anti-retroviral abacavir (ABC) y su frecuencia en la población peruana todavía es desconocida. El objetivo fue identificar el alelo HLA B*57:01 en una población militar de Lima, Perú. Se reclutaron 43 personas viviendo con VIH (PVV) quienes aceptaron participar a través de un consentimiento informado. La detección del alelo HLA B*57:01 se realizó mediante RPC en tiempo real (RT-PCR). Asimismo, se determinó la carga viral (CV), el recuento de linfocitos CD4 y la genotipificación del VIH. Se identificaron dos casos positivos al alelo HLA B*57:01 (4,7%). Además, uno de ellos presentó múltiples mutaciones de resistencia a los anti-retrovirales (ARV), incluyendo ABC. Se demostró por primera vez en el Perú la presencia del alelo HLA B*57:01.

The HLA B*57:01 allele is a genetic marker associated with hypersensitivity to the antiretroviral Abacavir (ABC) and its frequency in the Peruvian population is still unknown. The objective was to identify the HLA B*57:01 allele in a military population from Lima, Peru. Forty three people living with HIV (PLWH) were recruited, who agreed to participate through informed consent. Detection of the HLA B*57:01 allele was performed by real-time PCR (RT-PCR). Likewise, viral load (VL), CD4 lymphocyte count and HIV genotyping were determined. Two cases positive for the HLA B*57:01 allele (4.7%) were identified. In addition, one of them had multiple resistance mutations to antiretrovirals (ARVs), including ABC. The presence of the HLA B*57:01 allele was demonstrated for the first time in Peru.

Caracterización clínica de la Nefropatía por Poliomavirus BK en pacientes trasplantados renales / Clinical characterization of Polyomavirus BK nephropathy in kidney transplanted patients

INTRODUCCIÓN. La nefropatía por poliomavirus BK resulta un problema emergente en el trasplante renal, pues contribuye a la pérdida temprana de los injertos renales. OBJETIVO. Caracterizar clínicamente a los pacientes trasplantados renales con nefropatía por poliomavirus BK. MATERIALES Y MÉTODOS. Estudio observacional, descriptivo, realizado en el Hospital de Especialidades Carlos Andrade Marín en el período 2013-2022, se obtuvo una base de datos anonimizada, 479 pacientes trasplantados renales, de estos se identificaron 37 pacientes que corresponde a un 7,7% con nefropatía por poliomavirus BK, se realizó un análisis con el programa estadístico SPSS v26®. RESULTADOS. La población estuvo caracterizada por pacientes del sexo masculino (56,8%), con una edad media de 48,2 años, el donante cadavérico fue el más frecuente (94,5%), la mayor parte del tratamiento de la nefropatía por poliomavirus BK consistió en cambio de micofenolato sódico a everolimus y se mantuvo con 50% de Tacrolimus y Prednisona (40,5%); al valorar el cambio de los valores de creatinina, los niveles más elevados fueros a los 12 meses cuando la pérdida renal fue temprana (p: 0,042), y de la misma manera a los 12 meses, fueron más elevados los niveles de creatinina cuando el diagnóstico histopatológico fue Nefropatía por Poliomavirus Clase 3 (p: 0,01). DISCUSIÓN. La prevalencia de la nefropatía se mantuvo por debajo del 10% reportado a nivel global, la creatinina empeoró en pacientes con pérdida temprana del injerto renal y con una clase patológica avanzada, hecho reportado en la fisiopatología de la enfermedad. CONCLUSIÓN. La pérdida del injerto renal temprano presentó una creatinina más alta que la tardía. Es recomendable un tamizaje adecuado para la detección temprana del virus BK siendo crucial para prevenir el deterioro de la función renal y limitar la posterior pérdida del injerto.

INTRODUCTION: BK polyomavirus nephropathy is emerging as a significant concern in kidney transplantation, as it contributes to the early loss of renal grafts. OBJECTIVE: The aim of this study was to clinically characterize renal transplant recipients with BK polyomavirus nephropathy. MATERIALS AND METHODS: An observational and descriptive study was conducted at Carlos Andrade Marín Specialties Hospital during the period of 2013 to 2022. An anonymized database comprising 479 renal transplant patients was utilized. Among these, 37 patients, constituting 7.7%, were identified with BK polyomavirus nephropathy. Data analysis was performed using the statistical program SPSS v26®. RESULTS: The study population was predominantly composed of male patients (56.8%) with a mean age of 48.2 years. Deceased donors accounted for the majority (94.5%) of cases. The primary approach for managing BK polyomavirus nephropathy involved transitioning from mycophenolate sodium to everolimus, alongside maintaining a regimen of 50% tacrolimus and 40.5% prednisone. When assessing changes in creatinine values, the highest levels were observed at 12 months, coinciding with early renal loss (p: 0.042). Similarly, at the 12-month mark, elevated creatinine levels were associated with a histopathological diagnosis of Polyomavirus nephropathy Class 3 (p: 0.01). DISCUSSION: The prevalence of nephropathy remained below the globally reported threshold of 10%. Creatinine levels worsened in patients experiencing early graft loss and an advanced pathological classification, aligning with established disease pathophysiology. CONCLUSION: Early renal graft loss was associated with higher creatinine levels compared to delayed loss. Adequate screening for early detection of BK virus is recommended, as it plays a crucial role in preventing renal function deterioration and limiting subsequent graft loss.

Perfil clinico-epidemiológico e factores associados à não supressão viral em pacientes vivendo com hiv/sida assistidos no centro integrado de tratamento no hospital militar de maputo (citra/hmm), 2019 à 2020 / Clinical-epidemiological profile and factors associated with viral non-suppression in patients living with hiv/aids assisted at the integrated treatment center at the maputo military hospital (citra/hmm), 2019 to 2020

: Introdução: O HIV e SIDA é um problema de saúde pública global, responsável por cerca de 32.7 milhões de mortes de doenças relacionadas à SIDA desde o início da epidemia até o final de 2019, comprometendo a saúde, a força de produção e produtividade. Esse cenário tende a ser mais grave, quando se trata de forças militares, cuja a responsabilidade da defesa e manutenção da paz, recai sobre eles. O objectivo foi avaliar o perfil clinico-epidemiológico e factores associados a não supressão viral em pacientes vivendo com HIV/SIDA assistidas no Centro Integrado de Tratamento no Hospital Militar de Maputo (CITRA/HMM). Métodos: Tratou-se de um estudo transversal analítico com uma abordagem quantitativa, utilizando dados secundários de pacientes em seguimento entre os anos de 2019-2020 no CITRA/HMM. A amostra foi composta por 9.015 indivíduos com idade igual ou superiora 15 anos de idade. A analise de dados foi feita com pacote estatístico STATA versão 16, onde recorreu-se os testes Qui-quadrado de Pearson e a razão de chances/OR com Intervalos de Confiança/IC de 95% e p<0,05, para verificar as diferenças entre às proporções e a associação entre as variáveis em análise, considerando como desfecho o estado de supressão viral: suprimido (<1000 cópias de RNA do HIV/ml) e não suprimido (≥1000 cópias de RNA do HIV/ml). Para o modelo de regressão logística múltipla, apenas foram seleccionadas as variáveis que se mostraram estatisticamente significativas na análise bivariada. Resultados: Dos 9.105 indivíduos inclusos na análise, 4.808 (52,8%) eram do sexo feminino e 1.235 (13,6%) eram militares. A média de idade foi de 47,9 anos (DP±12,1), sendo o grupo etário mais prevalente composto por indivíduos com idades entre 25 e 59 anos, totalizando 7.297 (80,2%) participantes. Entre os analisados, 5.395 (53,3%) tinham resultados de última carga viral, e destes, 4.148 (76,9%) tinham a carga viral suprimida. Embora a maior proporção de supressão viral tenha sido verificada em civis, quando ajustada, essa diferença não demonstrou significância estatística…

Introduction: HIV and AIDS is a global public health problem, responsible for about 32.7 million deaths from AIDS-related diseases from the beginning of the epidemic to the end of 2019, compromising health, workforce and productivity. This scenario tends to be more serious when it comes to military forces, whose responsibility for the defense and maintenance of peace falls on them. The objective was to evaluate the clinical and epidemiological profile and factors associated with viral load non-suppression in patients living with HIV/AIDS at the Military Hospital (CITRA/HMM). Methods: This is a analytic cross-sectional study with a quantitative approach, using secondary data from patients being followed up between the years 2019-2020 at CITRA/HMM. The sample consisted of 9,015 individuals aged 15 years and over. Data analysis was performed with the statistical package STATA, Version 16. Pearson's chi-square test and odds ratio/OR with a confidence interval of 95%CI and p<0,05 were used to verify the differences between the proportions and association between the variables under analysis, considering the state of viral suppression as an outcome: suppressed (<1000 HIV RNA copies/ml) and non-suppressed (≥1000 HIV RNA copies/ml). For the multiple logistic regression model, only the variables that proved to be statistically significant in the bivariate analysis were selected. Results: Of the 9,105 individuals included in the analysis, 4,808 (52.8%) were female and 1,235 (13.6%) were military personnel. The average age was 47.9 years (SD±12.1), with the most prevalent age group being individuals aged between 25 and 59, totalling 7,297 (80.2%) participants. Among those analysed, 5,395 (53.3%) had their last viral load results, and of these, 4,148 (76.9%) had a suppressed viral load. Although the highest proportion of viral suppression was seen in civilians, when adjusted, this difference was not statistically significant…

Cycle threshold and viral load in SARS-CoV-2-infected patients in Sonora, Mexico.

BACKGROUND: SARS-CoV-2 infection is confirmed with the polymerase chain reaction test. Its positivity is determined by the cycle threshold (Ct), which is inversely proportional to viral load. OBJECTIVE: To describe clinical and epidemiological characteristics of SARS-CoV-2-infected patients according to their viral load estimated by Ct. MATERIAL AND METHODS: Cross-sectional study that included 21,110 confirmed cases, which were stratified according to their viral load: low (Ct > 30), medium (Ct 25-30) and high (Ct < 25). RESULTS: High viral load was identified in 53% of the cases, hospitalization was more common in subjects with medium viral load, and deaths were more prevalent in those with high viral load. Median Ct was lower during the first five days and linearly increased with the days of clinical evolution. There was a higher prevalence of deaths, hospitalizations and ventilatory support in subjects with confirmed SARS-CoV-2 infection who had a medium and high viral load. CONCLUSIONS: The Ct value, correlated with other patient characteristics, can guide the prognosis, as well as the design of interventions that limit the spread of the virus within the population.

ANTECEDENTES: La infección por SARS-CoV-2 se confirma con la prueba de reacción en cadena de la polimerasa. Su positividad se determina mediante el tiempo de ciclado (Ct, cycle threshold), el cual es inversamente proporcional a la carga viral. OBJETIVO: Describir las características clínicas y epidemiológicas de pacientes infectados por SARS-CoV-2 de acuerdo con su carga viral estimada mediante Ct. MATERIAL Y MÉTODOS: Estudio transversal que incluyó 21 110 casos confirmados, los cuales fueron estratificados conforme a su carga viral: baja (Ct > 30), media (Ct 25-30) y alta (Ct < 25). RESULTADO: 53 % de los casos tuvo una carga viral alta, la hospitalización fue más frecuente en sujetos con carga viral media y las defunciones fueron más prevalentes en aquellos con carga viral alta. La mediana del Ct fue más baja durante los primeros cinco días y aumentó linealmente con los días de evolución clínica. Hubo una mayor prevalencia de defunciones, hospitalizaciones y apoyo ventilatorio en sujetos con infección confirmada por SARS-CoV-2 que presentaron carga viral media y alta. CONCLUSIONES: El valor de Ct, correlacionado con otras características del paciente, puede orientar el pronóstico, así como al diseño de intervenciones que limiten la diseminación poblacional del virus.

Tiempo de ciclado y carga viral en pacientes infectados por SARS-CoV-2 en Sonora, México / Cycle threshold and viral load in SARS-CoV-2-infected patients in Sonora, Mexico

Resumen Antecedentes: La infección por SARS-CoV-2 se confirma con la prueba de reacción en cadena de la polimerasa. Su positividad se determina mediante el tiempo de ciclado (Ct, cycle threshold), el cual es inversamente proporcional a la carga viral. Objetivo: Describir las características clínicas y epidemiológicas de pacientes infectados por SARS-CoV-2 de acuerdo con su carga viral estimada mediante Ct. Material y métodos: Estudio transversal que incluyó 21 110 casos confirmados, los cuales fueron estratificados conforme a su carga viral: baja (Ct > 30), media (Ct 25-30) y alta (Ct < 25). Resultado: 53 % de los casos tuvo una carga viral alta, la hospitalización fue más frecuente en sujetos con carga viral media y las defunciones fueron más prevalentes en aquellos con carga viral alta. La mediana del Ct fue más baja durante los primeros cinco días y aumentó linealmente con los días de evolución clínica. Hubo una mayor prevalencia de defunciones, hospitalizaciones y apoyo ventilatorio en sujetos con infección confirmada por SARS-CoV-2 que presentaron carga viral media y alta. Conclusiones: El valor de Ct, correlacionado con otras características del paciente, puede orientar el pronóstico, así como al diseño de intervenciones que limiten la diseminación poblacional del virus.

Abstract Background: SARS-CoV-2 infection is confirmed with the polymerase chain reaction test. Its positivity is determined by the cycle threshold (Ct), which is inversely proportional to viral load. Objective: To describe clinical and epidemiological characteristics of SARS-CoV-2-infected patients according to their viral load estimated by Ct. Material and methods: Cross-sectional study that included 21,110 confirmed cases, which were stratified according to their viral load: low (Ct > 30), medium (Ct 25-30) and high (Ct < 25). Results: High viral load was identified in 53% of the cases, hospitalization was more common in subjects with medium viral load, and deaths were more prevalent in those with high viral load. Median Ct was lower during the first five days and linearly increased with the days of clinical evolution. There was a higher prevalence of deaths, hospitalizations and ventilatory support in subjects with confirmed SARS-CoV-2 infection who had a medium and high viral load. Conclusions: The Ct value, correlated with other patient characteristics, can guide the prognosis, as well as the design of interventions that limit the spread of the virus within the population.

Comparison of SARS-CoV-2 viral load in asymptomatic and symptomatic children attended in a referral public pediatric hospital in Argentina / Comparación de la carga viral de SARS-CoV-2 en niños asintomáticos y sintomáticos atendidos en un hospital pediátrico público de referencia en Argentina

Abstract At present, different reports have shown that children reach similar SARS-CoV-2 viral load (VL) levels compared to adults; however, the impact of VL on children remains ambiguous when asymptomatic versus symptomatic cases are compared. Thus, the aim of this study was to assess VL at the time of diagnosis in asymptomatic and symptomatic SARS-CoV-2 infected children. VL analysis was retrospectively carried out from nasopharyngeal swabs on 82 SARS-CoV-2 infected children, from March to October 2020. Of the 82 children, 31 were asymptomatic. Symptomatic patients had significantly higher VL values compared to asymptomatic ones (median = 7.41 vs4.35 log10 copies/ml, respectively). Notwithstanding, 8 out of 31 asymptomatic children had high VL levels, overlapping levels observed above the first quartile in the symptomatic group. Analysis of different age groups revealed that median VL values were higher in the symptomatic groups, although there was only a significant difference in children younger than 5 years of age. On the other hand, there was no significant difference between the VL values from the 82 SARS-CoV-2 infected children according to age, sex, underlying disease, symptoms or severity of COVID-19 related disease. This study emphasizes the importance of VL analysis in SARS-CoV-2 infected children, who could contribute to viral spread in the community. This concern could be extended to healthcare workers, who are in contact with children.

Resumen Diferentes informes han demostrado que los ninos alcanzan niveles de carga viral (CV) de SARS-CoV-2 similares a los de los adultos, pero el impacto de la CV en los niños continua siendo incierto cuando se compara entre aquellos que son asintomáticos y sintomáticos. El objetivo de este estudio fue evaluar la CV al momento del diagnóstico en ninos asintomáticos y sintomáticos infectados por SARS-CoV-2. El análisis de CV se realizó retrospectivamente a partir de muestras de hisopados nasofaríngeos de 82 niños infectados por SARS-CoV-2 entre marzo y octubre de 2020. De ellos, 31 eran asintomáticos. Encontramos que el grupo sintomático tenía valores de CV significativamente más altos en comparación con el grupo asintomático (mediana = 7,41 vs. 4,35 log10 copias/ml, respectivamente). No obstante, 8 de los 31 ninos asintomáticos presentaron valores de CV elevados, equivalentes a los observados por encima del primer cuartil del grupo sintomático. El análisis por grupos de edad reveló que la mediana de CV fue más alta en los niños sintomáticos, aunque esta diferencia fue significativa solamente en los menores de 5 anos. A su vez, los valores de CV obtenidos a partir de los 82 niños infectados por SARS-CoV-2 no mostraron diferencias significativas según el grupo etario, el sexo, la enfermedad de base, los síntomas y la gravedad de la COVID-19. Este estudio enfatiza la necesidad del análisis de la CV en ninos infectados por SARS-CoV-2, quienes podrían contribuir a la propagación del virus en la comunidad. Esta preocupación podría extenderse a los trabajadores de la salud que están en contacto con los ninños.

Infección por VIH: carga viral plasmática intratratamiento en la era del "Indetectable = Intransmisible" / HIV infection: Plasma viral load intratratization in the era of the "undetectable = non transmissible"

Se acepta que los individuos infectados por el virus de la inmunodeficiencia humana (HIV) son incapaces de transmitir la infección por vía sexual mientras sus niveles de carga viral plasmática se mantengan indetectables. Con el propósito de estudiar qué porcentaje de infectados por el HIV cumple esa condición estudiamos una población de pacientes asistidos regularmente en un hospital general de agudos de la ciudad de Buenos Aires. Se incluyeron 298 individuos, 162 de ellos de sexo masculino (54.36%) con una edad (promedio ± desvío estándar) de 47.83 ± 11.69 años y un recuento de células CD4+ de 693.93 ± 363.87 x 106 células / mL de sangre periférica. La carga viral plasmática fue indetectable en 230 de los individuos estudiados (77.81%). Los 68 restantes (22.82%) mostraron en promedio 9856.67 ± 70922.11 copias / mL, siendo estos niveles mayores en hombres que en mujeres (17379.39 ± 95521.51 copias / mL vs 895.78 ± 5952.99 copias / mL, respectivamente; p=0.015, Student t test), lo que explicaría los recuentos de linfocitos CD4+ significativamente menores hallados en hombres.187 de 231 individuos que recibían su primer tratamiento antiretroviral (TARV) mostraron cargas virales indetectables (80,95%) versus 42 de 67 pacientes que habían recibido dos o más esquemas de tratamiento antirretroviral (61,69%; p= 0.002, prueba de 2 ). Estos resultados muestran que un porcentaje importante de infectados por el HIV continúan presentando cargas virales plasmáticas detectables a pesar del TARV, siendo capaces de transmitir la infección por vía sexual a sus parejas

It is widely accepted that HIV-infected subjects are incapable to transmit sexually the infection while their plasmatic viral load remains undetectable. In order to assess the percentage of HIV infected patients showing undetectable viral loads during their antiviral treatment we studied a population of patients regularly assisted at a general hospital. A total of 298 patients (162 men; 54.36%) were admitted to the study. The mean age was (mean ± standard deviation) 47.83 ± 11.69 years, and the mean CD4+ cell count was 693.93 ± 363.87 x 106 cells / mL. These variables did not showed statistically significative differences between men and women. Plasmatic viral load was undetectable in 230 patients (77.81%). The remaining 68 patients (22.82%) showed a mean of 9856.67 ± 70922 copies / mL. These values were higher in men than in women (17379.39 ± 95521.51 copies / mL vs 895.78 ± 5952.99 copies / mL, respectively; p=0.015, Student t test). In line with these findings, CD4+ cell count was significantly lower in men (575.10 ± 345.14 cells / L vs. 707.04 ± 373.46 cells / L, respectively; p=0.0019, Student t test). 187 out of 231 patients receiving their first antiretroviral treatment showed undetectable viral loads (80,95%), while only 42 out of 67 patients having previously received other antiretroviral schemes had undetectable levels of plasmatic viral load (61,69%; p= 0.002, 2 ). These findings show that an important number of patients may keep detectable levels of plasmatic viral load during antiretroviral treatment, being therefore capable to sexually transmit the infection to their couples.

Utilidad de los enjuagues con povidona yodada y peróxido de hidrógeno en pacientes con COVID-19 / Utility of mouth rinses with povidone-iodine and hydrogen peroxide in patients with COVID-19

Introducción: La povidona yodada y el peróxido de hidrógeno podrían ser eficaces contra el SARS-CoV-2. Métodos: Estudio observacional de seguimiento prospectivo (EPA-AS) en 88 pacientes (43±17 años, 55% varones) con SARS-CoV-2 en muestras nasofaríngeas (RT-PCR). Treinta y uno recibieron enjuagues/gargarismos con povidona yodada cada 8h 2 días consecutivos, 17 con la misma pauta de peróxido de hidrógeno y 40 controles sin enjuagues. Se repitió PCR a los 3, 11 y 17 días. Resultados: Tras la intervención no hubo diferencias en la carga viral: povidona yodada (4,3±2,7 copias/ml), peróxido de hidrógeno (4,6±2,9 copias/ml), controles (4,4±3,0 copias/ml). El porcentaje de pacientes con una 2.ª PCR negativa fue 27% povidona yodada, 23% peróxido de hidrógeno y 32% controles; en la 3.ª PCR 62%, 54% y 58% respectivamente y en la 4.ª PCR, 81%, 75% y 81%. Conclusión: Nuestros resultados no apoyan la utilidad de los enjuagues de estos 2 antisépticos en pacientes con COVID-19.(AU)

Introduction: Povidone-iodine and hydrogen peroxide could be effective in against SARS-CoV-2. Methods: A “non-interventional trial” in 88 patients (43±17 yrs, 55% men) with SARS-CoV-2 in nasopharyngeal swabs (RT-PCR). 31 received mouth rinses/gargling with povidone-iodine (every 8h, two consecutive days), 17 with mouth rinses/gargling of hydrogen peroxide, and 40 controls. PCR were repeated at 3, 11 and 17 days. Results: After intervention the viral load (Log10copies/ml) remained similar in povidone-iodine (4.3±2.7copies/ml), hydrogen peroxide (4.6±2.9copies/ml; p=0.40) and controls (4.4±3.0copies/ml). The percentage of patients with a negative result in the second PCR was 27% in povidone-iodine group, 23% in hydrogen peroxide and 32% in controls; in the third PCR, 62%, 54% and 58% respectively; and in the fourth PCR, 81%, 75% and 81%. Conclusion: Our results do not support the clinical usefulness of mouth rinses/gargling with povidone-iodine or hydrogen peroxide in patients with COVID-19.(AU)

A Mouthwash with Cetylpyridinium Chlorideis reducing salivary SARS-CoV-2 viral load in +COVID-19 / Un enjuague con Cloruro de Cetilpiridinio redujo la carga salival del virus SARSCoV-2 en pacientes con Covid-19

Aim: The aim of this randomised, double-blind, placebo-controlled pilot clinical trial is to evaluate the capacity of a mouthwash to reduce SARS-CoV-2 viral load in the saliva of patients with COVID-19. Methods: Twenty-three symptomatic SARS-CoV-2-positive outpatients were selected andrandomised into two groups and registered at NTC 04563689. Both groups rinsed and gargled for one minute with either distilled water (Placebo) or with 0.05% Cetylpyridinium chloride (CPC) plus 0.12% Chlorhexidine (CHX) mouthwash (PERIOAID Intensive Care). Saliva samples were collected before the use of placebo or mouthwash and after 15 minutes and 1 and 2 hours of either of the above treatment. A saliva sample was also taken five days after regular use of placebo or mouthwash twice daily. The virus was detected by qRT-PCR. Results: A great heterogeneity in the viral load values was observed at baseline in both groups for nasopharyngeal and saliva samples. Most of the patients who used the mouthwash (8/12) had a significant decrease in baseline viral load after 15 min (greater than 99% reduction). This inhibitory effect was maintained for up to two hours in 10 of the 12 patients. At five days, SARS-CoV-2 RNA was detectedin only 1 patient from the mouthwash group and in 5 from the placebo group. Conclusions: This study points out that a CPC mouthwash can reduce the viral load in saliva of COVID-positive patients. This finding may be important in transmission control of SARS-CoV-2. Nevertheless, the clinical relevance of CPC mouthwash-reduction on SARS-CoV-2 shedding in saliva requires further study.

Objetivo: El objetivo de este ensayo clínico piloto aleatorizado, doble ciego y controlado con placebo es evaluar la capacidad de un enjuague bucal para reducir la carga viral del SARS-CoV-2 en la saliva de pacientes con COVID-19. Materiales y métodos:Veintitrés pacientes ambulatorios positivos para SARS-CoV-2 sintomáticos fueron seleccionados y aleatorizados en dos grupos y registrados en el NTC 04563689. Ambos grupos se enjuagaron y hicieron gárgaras durante un minuto con agua destilada (placebo) o con cloruro decetilpiridinio al 0 ,05 % (CPC). ) más enjuague bucal con Clorhexidina (CHX) al 0,12% (PERIOAID Intensive Care). Se recolectaron muestras de saliva antes del uso de placebo o enjuague bucal y después de 15 minutos y 1 y 2 horas de cualquiera de los tratamientos anteriores. También se tomó una muestra de saliva cinco días después del uso regular de placebo o enjuague bucal dos veces al día. El virus fue detectado por qRT-PCR. Resultados:Se demostró una gran heterogeneidad en los valores de carga viral al inicio del estudio en grupos ambos para muestras de nasofaringe y saliva. La mayoría de los pacientes que usaron el enjuague bucal (8/12) tuvieron una disminución significativa en la carga viral inicial después de 15 minutos (reducción superior al 99 %). Este efecto inhibidor se mantuvo hasta dos horas en 10 de los 12 pacientes. A los cinco días, se detectó ARN del SARS-CoV-2 en solo 1 paciente del grupo de enjuague bucal y en 5 del grupo de placebo. Conclusiones:Este señala que un enjuague bucal CPC puedereducir la carga viral en saliva de pacientes COVID positivos. Este hallazgo puede ser importante en el control de la transmisión del SARS-CoV-2. Sin embargo, la relevancia clínica de la reducción del enjuague bucal con CPC en la excreción de SARS-CoV-2 en la saliva requiere más estudios.

Comparison of SARS-CoV-2 viral load in asymptomatic and symptomatic children attended in a referral public pediatric hospital in Argentina.

At present, different reports have shown that children reach similar SARS-CoV-2 viral load (VL) levels compared to adults; however, the impact of VL on children remains ambiguous when asymptomatic versus symptomatic cases are compared. Thus, the aim of this study was to assess VL at the time of diagnosis in asymptomatic and symptomatic SARS-CoV-2 infected children. VL analysis was retrospectively carried out from nasopharyngeal swabs on 82 SARS-CoV-2 infected children, from March to October 2020. Of the 82 children, 31 were asymptomatic. Symptomatic patients had significantly higher VL values compared to asymptomatic ones (median=7.41 vs 4.35log10 copies/ml, respectively). Notwithstanding, 8 out of 31 asymptomatic children had high VL levels, overlapping levels observed above the first quartile in the symptomatic group. Analysis of different age groups revealed that median VL values were higher in the symptomatic groups, although there was only a significant difference in children younger than 5 years of age. On the other hand, there was no significant difference between the VL values from the 82 SARS-CoV-2 infected children according to age, sex, underlying disease, symptoms or severity of COVID-19 related disease. This study emphasizes the importance of VL analysis in SARS-CoV-2 infected children, who could contribute to viral spread in the community. This concern could be extended to healthcare workers, who are in contact with children.

Utility of mouth rinses with povidone-iodine and hydrogen peroxide in patients with COVID-19.

INTRODUCTION: Povidone-iodine and hydrogen peroxide could be effective in against SARS-CoV-2. METHODS: A "non-interventional trial" in 88 patients (43±17 yrs., 55% men) with SARS-CoV-2 in nasopharyngeal swabs (RT-PCR). 31 received mouth rinses/gargling with povidone-iodine (every 8h, two consecutive days), 17 with mouth rinses/gargling of hydrogen peroxide, and 40 controls. Were repeated PCR in 3, 11 and 17 days. RESULTS: After intervention the viral load (Log10 copies/ml) remained similar in povidone-iodine (4.3±2.7 copies/ml), hydrogen peroxide (4.6±2.9 copies/ml; p=0.40) and controls (4.4±3.0 copies/ml). The percentage of patients with a negative result in the second PCR was 27% in povidone-iodine group, 23% in hydrogen peroxide and 32% in controls; in the third PCR, 62%, 54% y 58% respectively; and in the fourth PCR, 81%, 75% y 81%. CONCLUSION: Our results do not support the clinical usefulness of mouth rinses/gargling with povidone-iodine or hydrogen peroxide in patients with COVID-19.

"Tô tranquila, estou com meus exames indetectáveis": as relações afetivo-sexuais de mulheres jovens vivendo com HIV com carga viral indetectável / "I'm calm, I have my undetectable exams": the affective-sexual relationships of young women living with HIV with an undetectable viral load / "Estoy tranquila, tengo mis exámenes de laboratorio indetectables": las relaciones afectivo-sexuales de mujeres jovenes viviendo con VIH con carga viral indetectable

Resumo Neste artigo, discutimos de que modo o discurso biomédico sobre carga viral indetectável (re)organiza as trajetórias afetivas e sexuais de mulheres jovens vivendo com HIV. Realizamos entrevistas semiestruturadas com cinco jovens vivendo com HIV/aids, com idade entre 18 e 30 anos, tanto pela internet, como em um serviço de saúde especializado (SAE) em Salvador-Ba, no período entre 2015 e 2017. As interações online aconteceram através do Whatsapp e Facebook. As jovens vivenciam a necessidade de negociar o prazer e a prevenção. Posicionam-se como sujeitos de "risco" e adotam a noção de carga viral indetectável como forma de sentirem-se seguras na prevenção. Os novos discursos biomédicos são incorporados em seus cotidianos, e os sentimentos de medo, rejeição e a "possibilidade" de "perigo" para o outro (soronegativo) contribuem para a reorganização de suas vidas e de seus relacionamentos.

Abstract In this article, we discuss how the biomedical discourse of undetectable viral load reorganises the affective and sexual trajectories of young women living with HIV. We conducted semi-structured interviews with five young women living with HIV/AIDS, aged between 18 and 30 yo, on the internet and at a specialized health service (SAE) in Salvador-Ba, between 2015 and 2017. The online interactions occurred through Whatsapp and Facebook. Young women experience the need to negotiate pleasure and prevention. They position herself as at "risk" subjects and adopt the notion of undetectable viral load as a way to feel safe in prevention. The new biomedical discourses are incorporated into their daily lives, and the fear, rejection and "possibility" of "danger" for another (seronegative) contributed to the reorganization of their lives and relationships.

Resumen En este artículo, discutimos cómo el discurso biomédico sobre la carga viral indetectable (re)organiza las trayectorias afectivas y sexuales de las mujeres jovens que viven con el VIH. Realizamos entrevistas semiestructuradas con cinco jovenes que viven con VIH/ SIDA, con edades entre 18 y 30 años, tanto en línea como en un servicio especializado de salud (SAE) en Salvador-Ba, entre 2015 y 2017. Las interacciones en línea ocorrieron través de Whatsapp y Facebook. Las mujeres jóvenes experimentan la necesidad de negociar el placer y la prevención. Se posicionan como sujetos de "riesgo" y adoptan la noción de una carga viral indetectable como forma de sentirse seguras en la prevención. Los nuevos discursos biomédicos se incorporan a su cotidianidad, y los sentimientos de miedo, rechazo y "posibilidad" de "peligro" para el otro (seronegativo) contribuyen a la reorganización de sus vidas y relaciones.

Recuento de linfocitos CD4, carga viral y colonización oral por Candida en personas viviendo con VIH/SIDA

Objetivos: determinar la correlación entre el recuento de CD4, carga viral y la colonización oral por Candida en personas viviendo con VIH/SIDA (PVVS) que reciben terapia antirretroviral (TAR). Métodos: se realizó un estudio transversal correlacional con 35 participantes que recibían tratamiento antirretroviral. Mediante citometría de flujo se determinó el recuento de CD4; la carga viral se determinó mediante RT-PCRq y la confirmación de colonización oral se realizó mediante aislamiento de Candida spp. Resultados: el recuento de CD4 se correlacionó significativamente de manera inversa con la carga viral (rho de Spearman = -0,457, p=0,006; Kendall Tau-b= -0,306, p=0,012) y con la colonización oral por Candida (rho de Spearman = -0,442, p=0,008; Kendall Tau-b= -0,366, p=0,010), no se encontró significancia estadística entre la carga viral y colonización (p>0,05). Conclusiones: En las PVVS que reciben TAR, los recuentos bajos de CD4 se relacionan con mayor colonización oral por Candida, no se encontró asociación de dicha colonización con la carga viral.

Objectives: to determine the correlation between CD4 count, viral load, and oral Candida colonization in people living with HIV/AIDS (PLWHA) receiving antiretroviral therapy (ART). Methods: a correlational cross-sectional study was conducted with 35 participants receiving antiretroviral treatment. Using flow cytometry, the CD4 count was determined; the viral load was determined by RT-PCRq and confirmation of oral colonization was made by isolating Candida spp. Results: CD4 count was significantly inversely correlated with viral load (Spearman's rho = -0.457, p=0.006; Kendall Tau-b= -0.306, p=0.012) and with oral Candida colonization (Spearman's rho = -0.442, p=0.008; Kendall Tau-b= -0.366, p=0,010), no statistical significance was found between viral load and colonization (p>0.05). Conclusions: in PLWHA receiving ART, low CD4 counts are associated with greater oral colonization by Candida; no association of said colonization with viral load was found.

Upper respiratory tract viral load quantification in COVID-19 patients at hospital admission and its association with disease severity.

INTRODUCTION: There are aspects of COVID-19 pathogenesis that are still unknown. OBJECTIVE: To determine the relationship between severity, mortality and viral replication in patients with COVID-19. METHODS: Clinical characteristics, severity and mortality of 203 patients hospitalized for COVID-19 were analyzed and correlated with viral load (VL) and threshold cycle (TC) at admission; nasopharyngeal swab was obtained. RESULTS: Mean VLs in surviving patients with mild to moderate, moderate to severe and severe disease were the following: 6.8 x 106, 7.6 x 107 and 1.0 x 109, respectively; and in patients with critical disease who died, VL was 1.70 x 109. TCs were 26.06, 24.07, 22.66 and 21.78 for the same groups. In those who died, a higher mean VL was observed at admission in comparison with those who survived (1.7 x 109 vs. 9.84 x 106; p < 0.001). A significant correlation was observed between VL, severity and death (r = 0.254, p < 0.045 and r = 0.21, p < 0.015). High VL was associated with increased in-hospital mortality in comparison with low VL (OR = 2.926, p < 0.017). CONCLUSION: SARS-CoV-2 VL determined at hospital admission might classify risk simultaneously with other factors described in COVID-19.

INTRODUCCIÓN: Aún se desconocen aspectos de la patogenia de COVID-19. OBJETIVO: Determinar la relación entre gravedad, mortalidad y replicación viral en pacientes con COVID-19. MÉTODOS: Se analizaron características clínicas, gravedad de la enfermedad y mortalidad de 203 pacientes hospitalizados por COVID-19 y se correlacionaron con carga viral (CV) y ciclo umbral (Ct) al ingreso; se tomó hisopado nasofaríngeo. RESULTADOS: Las CV medias en los pacientes sobrevivientes fueron las siguientes ante enfermedad leve a moderada, moderada a grave y grave: 6.8 × 106, 7.6 × 107 y 1.0 × 109; y en los pacientes con enfermedad crítica que fallecieron, la CV fue de 1.70 × 109. Los Ct fueron 26.06, 24.07, 22.66 y 21.78 para esos mismos grupos. En quienes fallecieron se observó mayor CV media al ingreso en comparación con quienes sobrevivieron (1.7 × 109 versus 9.84 × 106), p < 0.001. Se evidenció correlación significativa entre CV, gravedad y muerte (r = 0.254, p < 0.045 y r = 0.21, p < 0.015). La CV alta se asoció a mayor mortalidad intrahospitalaria en comparación con la CV baja (RM = 2.926, p < 0.017). CONCLUSIÓN: La CV de SARS-CoV-2 determinada al ingreso hospitalario podría calificar el riesgo simultáneamente con otros factores descritos en COVID-19.

Manifestaciones bucales en pacientes con SIDA bajo terapia antirretroviral en un hospital en Perú / Oral manifestations in AIDS patients receiving antiretroviral therapy in a referral hospital in Peru

Resumen Objetivo: Determinar la prevalencia de las manifestaciones bucales, en pacientes con SIDA bajo terapia antirretroviral en un Hospital Referencial en Perú. Materiales y métodos: Estudio prospectivo, no experimental, transversal y cuantitativo. Se contó con una población de 380 y una muestra de 191 pacientes, que cumplieron los criterios de selección. El instrumento utilizado fue una ficha de recolección de datos adaptada, que consta de dos partes, en una los datos personales y en otra las manifestaciones bucales más frecuentes. Resultados: La prevalencia de las manifestaciones bucales en pacientes con SIDA bajo terapia antirretroviral en un 59.50%, siendo la candidiasis oral la más frecuente con un 35.5%; El predominio de estas manifestaciones bucales es mayor en el género masculino con un 67% y en el rango de edades entre 18-25 años en un 57%. Conclusiones: Existe alta prevalencia de manifestaciones bucales en pacientes con SIDA bajo terapia antirretroviral, siendo la más frecuente la candidiasis oral, en el género masculino y en menores de 25 años.

Abstract Objective: TodeterminetheprevalenceoforalmanifestationsinAIDS patients, under antiretroviral therapy in a referral hospital in Perú. Materials and methods: A prospective, not experimental, cross - sectional and quantitative study. There was a population consisting of 380 and a sample of 191 patients who met the selection criteria. The instrument was an adapted data collection form that consist of two parts, in one the personal data and in another the most frequent oral manifestations. Results: The prevalence of oral manifestations in AIDS patients under antiretroviral therapy in 59.50% with oral candidiasis being the most frequent with 35.5%, the prevalence of oral manifestations is higher in male gender with a 67% and in the age range between 18-25 years old in a 57%. Conclusions: There is a high prevalence of oral manifestations in patients with AIDS under antiretroviral therapy, the most frequent being oral candidiasis in males and in those under 25 years old.

Perfil sociodemográfico e farmacoepidemiológico de crianças infectadas pelo HIV / Sociodemographic and pharmacoepidemiology profile of HIV infected children

RESUMO A terapia antirretroviral interfere na replicação do vírus HIV, impede a progressão da infecção para a Aids e previne a mortalidade precoce das crianças infectadas. Esta pesquisa investigou o perfil sociodemográfico e os parâmetros relacionados com o tratamento antirretroviral das crianças HIV positivas residentes no estado do Paraná. Trata-se de um estudo observacional descritivo e analítico realizado com dados secundários do ano de 2020 referentes às crianças com até 12 anos de idade. Foram investigados: perfil, prevalência, medicamentos em uso, abandono da terapia, resistência e supressão viral. Foram identificadas 148 crianças, com uma prevalência igual a 8,1/100 mil no Paraná. Apesar de todas as crianças diagnosticadas com HIV terem iniciado o tratamento, 17,2% encontravam-se em abandono da terapia antirretroviral. Entre as crianças que permaneciam em tratamento, 9,8% não atingiram a supressão viral e suas cargas virais comumente ultrapassavam mil cópias virais/mL. Houve um predomínio de esquemas medicamentosos provavelmente prescritos após falhas terapêuticas. Os resultados indicam que o Paraná apresenta bons resultados quanto ao início rápido da terapia e à supressão viral das crianças. Entretanto, existe um número considerável de abandonos da terapia e de falhas terapêuticas, indicando a necessidade de reforçar a vinculação desta população aos serviços de saúde.

ABSTRACT Antiretroviral therapy interferes with the replication of the HIV virus, stops the progression of infection, and prevents early mortality in infected children. This research investigated the sociodemographic profile and parameters related to the antiretroviral treatment of HIV positive children living in the state of Paraná. This is a descriptive observational and analytical study, carried out with secondary data from the year 2020, referring to children up to 12 years of age. The profile, prevalence, medicines in use, treatment abandonment, viral resistance, and viral suppression were investigated. A total of 148 children were identified, with a prevalence equal to 8.1/100,000 in Paraná. All infants had begun their treatment, but 17,2% abandoned it. Among children who remained on treatment, 9.8% did not achieve viral suppression and their viral loads commonly exceeded 1000 viral copies/mL. There was a predominance of drug regimens probably prescribed after treatment failures. The results indicate that Paraná presents good results in terms of rapid initiation of therapy and viral suppression in children. However, there is a considerable number of abandonments of therapy and therapeutic failures, indicating the need to strengthen the link between this population and health services.

Cuantificación de la carga viral en el tracto respiratorio superior en pacientes con COVID-19 al ingreso hospitalario y su asociación con la gravedad de la enfermedad / Upper respiratory tract viral load quantification in COVID-19 patients at hospital admission and its association with disease severity

Resumen Introducción: Aún se desconocen aspectos de la patogenia de COVID-19. Objetivo: Determinar la relación entre gravedad, mortalidad y replicación viral en pacientes con COVID-19. Métodos: Se analizaron características clínicas, gravedad de la enfermedad y mortalidad de 203 pacientes hospitalizados por COVID-19 y se correlacionaron con carga viral (CV) y ciclo umbral (Ct) al ingreso; se tomó hisopado nasofaríngeo. Resultados: Las CV medias en los pacientes sobrevivientes fueron las siguientes ante enfermedad leve a moderada, moderada a grave y grave: 6.8 × 106, 7.6 × 107 y 1.0 × 109; y en los pacientes con enfermedad crítica que fallecieron, la CV fue de 1.70 × 109. Los Ct fueron 26.06, 24.07, 22.66 y 21.78 para esos mismos grupos. En quienes fallecieron se observó mayor CV media al ingreso en comparación con quienes sobrevivieron (1.7 × 109 versus 9.84 × 106), p < 0.001. Se evidenció correlación significativa entre CV, gravedad y muerte (r = 0.254, p < 0.045 y r = 0.21, p < 0.015). La CV alta se asoció a mayor mortalidad intrahospitalaria en comparación con la CV baja (RM = 2.926, p < 0.017). Conclusión: La CV de SARS-CoV-2 determinada al ingreso hospitalario podría calificar el riesgo simultáneamente con otros factores descritos en COVID-19.

Abstract Introduction: There are aspects of COVID-19 pathogenesis that are still unknown. Objective: To determine the relationship between severity, mortality and viral replication in patients with COVID-19. Methods: Clinical characteristics, severity and mortality of 203 patients hospitalized for COVID-19 were analyzed and correlated with viral load (VL) and threshold cycle (TC) at admission; nasopharyngeal swab was obtained. Results: Mean VLs in surviving patients with mild to moderate, moderate to severe and severe disease were the following: 6.8 × 106, 7.6 × 107 and 1.0 × 109, respectively; and in patients with critical disease who died, VL was 1.70 × 109. TCs were 26.06, 24.07, 22.66 and 21.78 for the same groups. In those who died, a higher mean VL was observed at admission in comparison with those who survived (1.7 × 109 vs 9.84 × 106; p < 0.001). A significant correlation was observed between VL, severity and death (r = 0.254, p < 0.045 and r = 0.21, p < 0.015). High VL was associated with increased in-hospital mortality in comparison with low VL (OR = 2.926, p < 0.017). Conclusion: SARS-CoV-2 VL determined at hospital admission might classify risk simultaneously with other factors described in COVID-19.

Factores asociados al fracaso virológico en pacientes VIH con tratamiento antirretroviral / Factors associated with virologic failure in HIV patients on antiretroviral therapy

Objetivo: Determinar los factores asociados al fracaso virológico enpacientes con el virus de la inmunodeficiencia humana con tratamientoantirretroviral atendidos en una institución de salud colombiana.Método: Estudio transversal, observacional, retrospectivo y analítico enpacientes con el virus de la inmunodeficiencia humana con tratamientoantirretroviral entre 2007-2020. Se recogieron variables sociodemográficas,farmacológicas y clínicas, incluyendo la carga viral, el grado de adherenciay la tasa de reclamación de medicamentos. Para el análisis estadístico seobtuvieron las odds ratio crudas y ajustadas y los intervalos de confianza.Resultados: De una población de 5.406 pacientes, la proporción defracaso virológico fue de 16,7% y en el modelo ajustado se encontró asociación entre el fracaso virológico con el tiempo en el tratamiento mayora un año, la tasa de posesión de la reclamación inferior al 80%, la noreclamación oportuna por omisión o suspensión, la adherencia inferior al85%, el recuento de CD4 inferior a 500, niveles de colesterol total mayores de 201 mg/dl, lipoproteína de alta densidad menor de 39 mg/dl ypresencia de micosis.Conclusiones: En nuestra cohorte de pacientes con el virus de la inmunodeficiencia humana, un menor tiempo en tratamiento, un recuento deCD4 menor de 200, una baja tasa de reclamación de los medicamentos,así como la no reclamación oportuna por omisión y suspensión y un menorgrado de adherencia son factores que se relacionan con el fracaso virológico. (AU)

Objective: To determine the factors associated with virologic failurein HIV patients on antiretroviral treatment treated in a Colombian healthinstitution.Method: This was a cross-sectional observational retrospective analytical study of HIV patients receiving antiretroviral treatment between2007-2020. Sociodemographic, pharmacological and clinical variableswere collected, including viral load, adherence, and the medication possession ratio. For statistical analysis, crude and adjusted odds ratios andconfidence intervals were obtained.Results: In a population of 5,406 patients, the proportion of virologicfailure was 16.7%. Moreover, in the adjusted model, an association wasfound between virologic failure and time on treatment greater than oneyear, medication possession ratio under 80%, failure to claim medications from the pharmacy due to dose omission or discontinuation, adherence under 85%, CD4 count under 500, total cholesterol levels above201 mg/dL, high density lipoproteins under 39 mg/dL and presence ofmycosis.Conclusions: In our cohort of HIV patients, short treatment periods, CD4counts under 200, a low medication possession ratio, failure to timelyclaim medications from the pharmacy due to omission or discontinuation,and a lower degree of adherence were factors related to virologic failure. (AU)

Acompanhamento do comportamento do HIV através de exames laboratoriais em portadora do vírus: relato de caso / Monitoring of HIV behavior through laboratory tests in a virus carrier: case report

O vírus da imunodeficiência humana é o agente etiológico da AIDS, doença crônica que destrói o sistema imunológico e é caracterizada pela baixa contagem de células TCD4, alta contagem de partículas virais no sangue e manifestações clínicas da doença. O diagnóstico se dá com o aparecimento de infecções oportunistas, que levam a contagem de TCD4 a níveis menores que 200 céls/mm³. Os exames laboratoriais para o diagnóstico do HIV foram os principais avanços para o início do tratamento, reduzindo a transmissão. Detecção de anticorpos, detecção de antígenos e amplificação do genoma do vírus são alguns dos exames laboratoriais utilizados para diagnóstico. Os dois principais biomarcadores são os exames de contagem de células TCD4, que verifica o sistema imune, e a quantificação de carga viral, que informa a quantidade de partículas virais, mostrando a progressão da infecção. Quanto maior a carga viral, maior o dano ao sistema imune. Uma carga viral indetectável é inferior a 50 cópias/mL, mas valores menores ou iguais a 200 cópias/mL também impedem a transmissão. Uma declaração de consenso afirma que Indetectável é igual a Intransmissível. Portanto, quando indetectável, a transmissão inexiste. O presente estudo relata e discute o caso clínico de uma paciente diagnosticada com HIV/AIDS aos 28 anos, que sobreviveu, apesar do diagnóstico tardio, e sob presença de doença oportunista com um grave grau de diminuição de células TCD4 (22 cél/mm³). Por meio do diagnóstico, introdução e adesão correta da terapia antirretroviral e monitorização de exames laboratoriais, conseguiu evitar a morte e ter uma vida semelhante à de um HIV negativo. Ultrapassou a expectativa de vida que na descoberta era de 10 anos, com uma qualidade de vida considerável, não sendo transmissora do vírus, diminuindo assim o estigma e preconceito. O biomédico é peça fundamental nesse contexto, considerando que deve fornecer informações precisas e fidedignas, tão necessárias ao acompanhamento de pessoas vivendo com HIV, para que autoridades e profissionais de saúde adotem medidas adequadas, tanto na prevenção, quanto no diagnóstico e monitoramento da doença.

The human immunodeficiency virus is the etiological agent of AIDS, a chronic disease that destroys the immune system and is characterized by low TCD4 cell count, high viral particle count in blood and clinical manifestations of the disease. The diagnosis is due to the appearance of opportunistic infections, which lead to TCD4 counts below 200 cells / mm³. Laboratory tests for the diagnosis of HIV were the main advances in starting treatment, reducing transmission. Antibody detection, antigen detection and virus genome amplification are some of the laboratory tests used for diagnosis. The two main biomarkers are the TCD4 cell count tests, which checks the immune system, and viral load quantification, which reports the number of viral particles, showing the progression of infection. The higher the viral load, the greater the damage to the immune system. An undetectable viral load is less than 50 copies / mL, but values less than or equal to 200 copies / mL also prevent transmission. A consensus statement states that Undetectable equals Non-Transmissible. Therefore, when undetectable, transmission does not exist. The present study reports and discusses the clinical case of a patient diagnosed with HIV / AIDS at age 28, who survived despite late diagnosis and under the presence of opportunistic disease with a severe degree of TCD4 cell reduction (22 cells / mm³). Through the diagnosis, introduction and correct adherence of antiretroviral therapy and monitoring of laboratory tests, she was able to avoid death and have a life similar to that of an HIV negative. Exceeded the life expectancy that in the discovery was 10 years, with a considerable quality of life, not transmitting the virus, thus reducing the stigma and prejudice. The biomedical is a key player in this context, considering that he must provide accurate and reliable information, which is so necessary for the monitoring of people living with HIV, so that authorities and health professionals adopt appropriate measures, both in prevention, diagnosis and monitoring of the disease.

Características clínico-sociodemográficas de pacientes con VIH/sida con complicaciones neurológicas por infecciones oportunistas en el Hospital Nacional Hipólito Unanue, 2017-2019

Objetivo: Describir las características clínicas y sociodemográficas de los pacientes con VIH/sida con complicaciones neurológicas por infecciones oportunistas en el Hospital Nacional Hipólito Unanue en Lima, Perú (2017-2019). Materiales y métodos: Se realizó un estudio observacional, descriptivo, transversal y retrospectivo. Se incluyeron historias clínicas de pacientes mayores de 18 años con diagnóstico de VIH/sida con complicaciones neurológicas por infecciones oportunistas. Las variables del estudio fueron analizadas con el programa SPSS versión 25 mediante estadística descriptiva. Resultados: Se analizaron 45 historias clínicas; la edad promedio fue 34,38 ± 11,19 años y el sexo predominante, el masculino (73,30 %). El 31,10 % procedía del distrito de Ate, el 53,30 % tenía secundaria completa y el 24,40 % eran desempleados. El 67,90 % (n = 19/28) eran heterosexuales y el 17,20 % tenía tuberculosis como comorbilidad. Las manifestaciones clínicas predominantes fueron cefalea (21,30 %) y alteración del nivel de conciencia (19 %). La tuberculosis cerebral y la neurotoxoplasmosis fueron las complicaciones neurológicas más frecuentes, ambas con 30,90 %. El 83,30 % (n = 25/30) de los sujetos tuvieron una carga viral >100,000 copias/ml; el 97,40 % (n = 38/39), un conteo de CD4 100,00 copias/ml, un conteo de CD4 <199 células/mm3 y pobre adherencia al TARGA.

Objective: To describe the clinical and sociodemographic characteristics of HIV/AIDS patients with neurological complications due to opportunistic infections at the Hospital Nacional Hipólito Unanue in Lima, Peru (2017-2019). Materials and methods: An observational, descriptive, cross-sectional and retrospective study was conducted with medical records of patients older than 18 years diagnosed with HIV/AIDS and neurological complications due to opportunistic infections. The study variables were analyzed with descriptive statistics using the IBM SPSS Statistics V25. Results: Forty-five (45) medical records were analyzed: the average age was 34.38 ± 11.19 years, 73.30 % were males, 31.10 % were from the district of Ate, 53.30 % completed secondary education, 24.40 % were unemployed, 67.90 % (n = 19/28) were heterosexual and 17.20 % had tuberculosis as comorbidity. The most common clinical manifestations were headache (21.30 %) and impaired consciousness (19 %). Cerebral tuberculosis and neurotoxoplasmosis were the most frequent neurological complications (30.90 % in both cases). Eighty-three point three zero percent (83.30 %) (n = 25/30) of the study subjects had a viral load > 100,000 copies/ml, 97.40 % (n = 38/39) had a CD4 count 100,000 copies/ml, CD4 count < 199 cells/mm3 and poor adherence to HAART.